SSY Group Limited Announces Potential Acquisition of Two Class 2 Modified New Drugs
Hong Kong, 4 June 2026 — SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) has announced a significant business development that could have material implications for the Company’s future growth and share value.
Key Points from the Report
- On 4 June 2026, SSY Group’s wholly-owned subsidiary, Shijiazhuang No. 4 Pharmaceutical Co., Ltd. (“Shijiazhuang No. 4”), entered into a letter of intent (LOI) with Anhui Xinzheng Heying Medical Technology Co., Ltd. (“Xinzheng Heying”) for a potential collaboration on two Class 2 modified new chemical drugs:
- Class 2.2 Antispasmodic Drug for Children
- Class 2.3 Drug Targeting Chronic Obstructive Pulmonary Diseases (COPD)
- The LOI outlines a framework for SSY Group to potentially acquire all technical knowhows, intellectual property rights, patents (including application rights), registration and filing data, and global exclusive commercial interests related to the two drugs.
- Xinzheng Heying is responsible for completing all research materials, including pharmaceutical, non-clinical, registration, and intellectual property documentation.
- Post-agreement, all rights and interests will be transferred to Shijiazhuang No. 4, with Xinzheng Heying retaining rights of attribution and eligibility for milestone payments.
- The LOI grants SSY Group a 90-day exclusivity period during which Xinzheng Heying cannot negotiate or provide information about these projects to any third party.
- SSY Group will conduct technical, legal, and financial due diligence before entering into a formal agreement. The LOI itself is not binding (except for the exclusivity provision) and will expire after 90 days unless a formal agreement is signed.
- Xinzheng Heying is an independent third party not connected with SSY Group or its connected persons.
Important Information for Shareholders
- The potential acquisition would give SSY Group exclusive global rights to two innovative drug candidates, significantly enhancing its portfolio and commercial prospects in the pharmaceutical industry.
- If realized, this project could have a positive impact on SSY Group’s growth and business development, potentially increasing shareholder value.
- No definitive agreement has been signed yet. The project remains subject to due diligence and negotiation of a formal agreement. There is a risk that the deal may not proceed.
- Shareholders and potential investors are advised to exercise caution when dealing in SSY Group shares as the outcome of this project remains uncertain and may influence the Company’s share price.
Additional Details
- The Group is primarily engaged in research, development, manufacturing, and sales of pharmaceutical products, including finished medicines, bulk pharmaceuticals, and medical materials.
- The Board of Directors believes the LOI and any potential transaction are fair and reasonable, and aligned with the interests of the Company and its shareholders.
- Further announcements will be made as appropriate in accordance with regulatory requirements.
- As of the announcement date, the Board comprises a mix of executive, non-executive, and independent non-executive directors.
Potential Share Price Impact: The exclusivity and potential acquisition of global rights to two high-value pharmaceutical assets represent a notable development. If the transaction is finalized, it could materially strengthen SSY Group’s product pipeline and future earnings prospects, making this a potentially price-sensitive event for investors.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. The project remains subject to due diligence and negotiation, and may or may not proceed. Investors should exercise caution when making investment decisions related to SSY Group Limited.
SSY集團有限公司簽訂意向書，有望收購兩項二類改良新藥
香港，2026年6月4日 — SSY集團有限公司（「公司」及其附屬公司，合稱「集團」）公佈一項重大業務發展，或對公司未來增長及股價產生重大影響。
報告重點
- 2026年6月4日，集團全資附屬公司石家莊四藥有限公司（「石家莊四藥」）與安徽鑫正合盈醫藥科技有限公司（「鑫正合盈」）簽訂意向書，擬合作開發兩款二類改良化學新藥：
- 二類2.2兒童鎮痙藥
- 二類2.3針對慢性阻塞性肺病（COPD）藥物
- 意向書擬定集團將有機會獲得相關藥物的全部技術、知識產權、專利（包括申請權）、註冊及申報數據，以及全球獨家商業利益。
- 鑫正合盈需完成所有研究資料，包括藥學研究、非臨床研究、註冊、知識產權等。
- 正式協議簽訂及預付款後，所有權利及利益將轉讓予石家莊四藥，鑫正合盈只保留署名權及里程碑付款權利。
- 意向書設有90天獨家期，期間鑫正合盈不得與第三方協商或洩露項目資料。
- 集團將於正式協議前進行技術、法律及財務盡職審查，意向書除獨家條款外不具法律約束力，90天後失效。
- 鑫正合盈為獨立第三方，與集團無關聯。
股東須知的重要事項
- 如項目落實，集團將獲得兩項創新藥全球獨家權利，極大增強產品線及商業前景。
- 項目若最終落實，預料將正面影響集團增長及業務發展，或提升股東價值。
- 目前尚未簽訂正式協議，項目仍需盡職審查及進一步談判，存在交易未能成事的風險。
- 建議股東及潛在投資者在買賣公司股份時保持審慎，因項目未有定案，相關消息或影響公司股價。
其他詳情
- 集團主要從事藥品的研發、生產及銷售，包括成品藥、原料藥及醫用材料。
- 董事會認為意向書及相關交易公平合理，符合公司及股東整體利益。
- 公司將根據監管要求適時發佈進一步公告。
- 公告發布時，董事會成員包括執行董事、非執行董事及獨立非執行董事。
潛在股價影響：獨家期及潛在收購兩項具價值藥物的全球權利，是集團發展的重要里程碑。若交易成事，將大幅強化產品管線及未來盈利能力，屬於潛在敏感及影響股價的重要消息。
免責聲明：本文章僅供參考，並不構成任何投資建議。項目仍需盡職審查及正式協議，未必最終達成。投資者應審慎考慮與SSY集團有限公司有關的投資決定。
